Skip to main content

Current Management of Angiosarcoma: Recent Advances and Lessons From the Past

Opinion statement

Despite their rarity, angiosarcomas are one of the most aggressive soft tissue sarcomas. Management can often be challenging due to their location and infiltrative nature. A multidisciplinary treatment approach is always warranted, but the recurrence remains high even for localized tumors despite multimodality treatment. In the metastatic setting, cytotoxic chemotherapies, targeted therapies, and, more recently, immunotherapy are used. The sequence of systemic therapies remains currently a topic of active investigation. Over the last couple of years, there have been significant advances in understanding angiosarcoma biology, most notably via patient-driven initiatives like the Angiosarcoma Project. The knowledge derived from such translational work has led to identifying potential biomarkers of response to treatments and exploring new therapeutic avenues. More clinical trials are underway to expand treatment options and improve patient outcomes.

This is a preview of subscription content, access via your institution.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Antonescu C. Malignant vascular tumors—an update. Mod Pathol. 2014;27:S30–8.

    CAS  Article  Google Scholar 

  2. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010 Jun;251(6):1098–106.

  3. Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer. 1996;77(11):2400–6.

    CAS  Article  Google Scholar 

  4. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010 Oct;11(10):983–91.

  5. Gaballah AH, Jensen CT, Palmquist S, Pickhardt PJ, Duran A, Broering G, et al. Angiosarcoma: clinical and imaging features from head to toe. Br J Radiol. 2017;90(1075):20170039.

    Article  Google Scholar 

  6. Florou V, Wilky BA. Current and future directions for angiosarcoma therapy. Curr Treat Options in Oncol. 2018;19(3):14.

    Article  Google Scholar 

  7. •• Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26(2):181–7 Results of the highly impactful Angiosarcoma Project in terms of expanding the knowledge on angiosarcoma at the tumor genomic level.

    CAS  Article  Google Scholar 

  8. Boichard A, Wagner MJ, Kurzrock R. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. Genome Med. 2020;12(1):61.

    CAS  Article  Google Scholar 

  9. Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, et al. Multiomic analysis and immune profiling reveal distinct subtypes of human angiosarcoma. J Clin Invest. 2020;130(11):5833–46.

    CAS  Article  Google Scholar 

  10. Weidema ME, van de Geer E, Koelsche C, Desar IME, Kemmeren P, Hillebrandt-Roeffen MHS, et al. DNA methylation profiling identifies distinct clusters in angiosarcomas. Clin Cancer Res. 2020;26(1):93–100.

    CAS  Article  Google Scholar 

  11. Co M, Lee A, Kwong A. Cutaneous angiosarcoma secondary to lymphoedema or radiation therapy — a systematic review. Clin Oncol. 2019 Apr;31(4):225–31.

  12. Palmerini E, Leithner A, Windhager R, Gosheger G, Boye K, Laitinen M, et al. Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). Sci Rep. 2020;10(1):10853.

    CAS  Article  Google Scholar 

  13. Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030–6.

    CAS  Article  Google Scholar 

  14. Heinhuis KM, IJzerman NS, van der Graaf WTA, Kerst JM, Schrage Y, Beijnen JH, et al. Neoadjuvant systemic treatment of primary angiosarcoma. Cancers (Basel). 2020;12(8):2251.

    CAS  Article  Google Scholar 

  15. Constantinidou A, Sauve N, Stacchiotti S, Blay J-Y, Vincenzi B, Grignani G, et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020;5(4):e000787.

    Article  Google Scholar 

  16. • Roy A, Gabani P, Davis EJ, Oppelt P, Merfeld E, Keedy VL, et al. Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. Clin Transl Radiat Oncol. 2021:114–20. First report on efficacy of concurrent chemoradiation in localized cutaneous angiosarcoma, that may change the standard approach in this setting if findings are confirmed in the ongoing phase II study.

  17. Young RJ, Natukunda A, Litière S, Woll PJ, Wardelmann E, Van Der Graaf WTA. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014;50(18):3178–86.

    CAS  Article  Google Scholar 

  18. D'Angelo SP, Munhoz RR, Kuk D, Landa J, Hartley EW, Bonafede M, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma. Oncology. 2015;89(4):205–14.

    CAS  Article  Google Scholar 

  19. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly Paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26(32):5269–74.

    CAS  Article  Google Scholar 

  20. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44(16):2433–6.

    CAS  Article  Google Scholar 

  21. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86(10):2034–7.

    CAS  Article  Google Scholar 

  22. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian rare cancer network. Ann Oncol. 2012;23(2):501–8.

    CAS  Article  Google Scholar 

  23. Tian Z, Zhang F, Li P, Wang J, Yang J, Zhang P, et al. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. BMC Cancer. 2020;20(1):698.

    CAS  Article  Google Scholar 

  24. Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, et al. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study. Br J Dermatol. 2020 Nov 26;183(5):831–9.

  25. Ravi V, Wagner M, Chen TW-W, Loong HHF, Mennel RG, Yen C-C, et al. A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma. J Clin Oncol. 2020;38(15_suppl):11517.

    Article  Google Scholar 

  26. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, et al. Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209(3):507–20.

    CAS  Article  Google Scholar 

  27. Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97(1):74–81.

    Article  Google Scholar 

  28. Zietz C, Rössle M, Haas C, Sendelhofert A, Hirschmann A, Stürzl M, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153(5):1425–33.

    CAS  Article  Google Scholar 

  29. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257–63.

    CAS  Article  Google Scholar 

  30. Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: A randomized phase II trial. J Clin Oncol. 2015;33(25):2797–802.

    CAS  Article  Google Scholar 

  31. Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma. 2015;2015:532478.

  32. Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol (Madr). 2017;56(1):88–92.

    Article  Google Scholar 

  33. von Mehren M, Litwin S, Ravi V, Schuetze S, Movva S, Agulnik M, et al. Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS). J Clin Oncol. 2019;37(15_suppl):11039.

    Article  Google Scholar 

  34. Ravi V, Sanford EM, Wang W-L, Ross JS, Ramesh N, Futreal A, et al. Antitumor response of VEGFR2- and VEGFR3-amplified angiosarcoma to pazopanib. J Natl Compr Canc Netw. 2016;14(5):499–502.

    CAS  Article  Google Scholar 

  35. Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1732–42.

    CAS  Article  Google Scholar 

  36. Agulnik M, Robinson SI, Okuno SH, Siontis B, Attia S, Kocherginsky M, et al. Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma. J Clin Oncol. 2020;38(15_suppl):11561.

    Article  Google Scholar 

  37. Jones R, Ravi V, Brohl AS, Chawla SP, Ganjoo K, Italiano A, et al. Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). Ann Oncol [Internet]. 2019 Oct;30:v683.

  38. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.

    CAS  Article  Google Scholar 

  39. Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother cancer. 2019;7(1):213.

    Article  Google Scholar 

  40. • Florou V, Espejo Freire A, Goel N, Rosenberg AE, Wilky BA, Trent JC. Safety and efficacy of immune checkpoint inhibitors in patients with angiosarcoma. In: CTOS Annual Meeting. 2019. First case series describing the use and efficacy of immune checkpoint inhibitors in patients with angiosarcoma.

  41. Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy—a case report. J Immunother cancer. 2017;5(1):58.

    Article  Google Scholar 

  42. Momen S, Fassihi H, Davies HR, Nikolaou C, Degasperi A, Stefanato CM, et al. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Mol Case Stud. 2019;5(5):a004408.

    Article  Google Scholar 

  43. Hamacher R, Kämpfe D, Reuter-Jessen K, Pöttgen C, Podleska LE, Farzaliyev F, et al. Dramatic response of a PD-L1–positive advanced angiosarcoma of the scalp to pembrolizumab. JCO Precis Oncol. 2018;16(2):1–7.

    Google Scholar 

  44. Wagner M, Othus M, Patel S, Ryan C, Sangal A, Powers B, et al. 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2020;8(Suppl 3):A843.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vaia Florou MD.

Ethics declarations

Conflict of interest

Vaia Florou declares that she has no conflict of interest.

Breelyn A. Wilky has received compensation from SpringWorks and Deciphera for service as a consultant.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Skin Cancer

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Florou, V., Wilky, B.A. Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. Curr. Treat. Options in Oncol. 22, 61 (2021). https://doi.org/10.1007/s11864-021-00858-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00858-9

Keywords

  • Angiosarcoma
  • Angiosarcoma Project
  • Immunotherapy